Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders

Figures & data

Table 1. Patients’demographics.

Variable	Value
Medical co-morbidity, n
Hypertension	16
DM	14
Hypertension and DM	15
Relevant surgical history, n
Transurethral surgery (TURP, BNI, TUIP)	6
Multiple transurethral surgeries	1
Smoking, n	21
Ages, years, mean (SD; range)	51 (11.56; 23–74)
Duration of ED, months, mean (SD; range)	34.5 (1.18; 9–60)
Baseline IIEF score, points, mean (SD; range)	11 (2.8; 6–16)
Baseline EHS, points, mean (range)	2 (1–2)
BMI, kg/m^2, mean (SD; range)	27.46 (2.8; 21.8–36.3)

BNI: bladder neck incision; TUIP: transurethral incision of the prostate.

Table 2. Factors that may influence Li-SWT outcome.

Variable	Responders	Non-responders	P
Number of patients	33	19
Age, years, mean (range)	46.5 (28–65)	62.5 (41–74)	0.031
ED duration, month, mean (range)	22.5 (9–36)	36.0 (12–60)	<0.001
ED severity, n (%)			0.02
Severe	8 (24.3)	14 (73.7)
Moderate	25 (75.7)	5 (26.3)
Hypertension, n (%)	10 (30.3)	6 (31.5)	0.66
DM, n (%)	9 (27.2)	5 (26.3)	0.71
Hypertension+ DM, n (%)	9 (27.3)	6 (31.5)	0.27
DM duration, months, mean (range)	33 (12–60)	32 (10–60)	0.28
Smoking, n (%)	13 (39.4)	8 (41.1)	0.34
Transurethral surgery, n (%)	4 (12.1)	3 (15.7)	0.54
BMI, kg/m^2, mean (range)	27.6 (20.12–31.5)	29.94 (26.32–36.36)	0.61
Penile CDU findings, n (%)			0.83
VOD	28 (85)	18 (94.7)
Arteriogenic	5 (15)	1 (5.3)